BOSTON — Pruritus and atopic dermatitis-related gene expression were altered after treatment with difelikefalin, according to a study presented at the American Academy of Dermatology Annual Meeting.
“The results of this study highlight the promising effect of difelikefalin (DFK), a novel oral kappa opioid receptor agonist, for the treatment of moderate to severe pruritus in patients affected by atopic dermatitis,” Paola Facheris, MD, of the laboratory of inflammatory skin diseases at the Icahn School of Medicine at Mount Sinai, told Healio. “Interestingly, we also saw